Search results

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

Result type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.

Result type

Technology appraisal guidance

Published

8 June 2022

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Discontinued [GID-TA10109]

Result type

Technology appraisal guidance

Status

Discontinued

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

7 June 2023

This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

Result type

Technology appraisal guidance

Published

2 June 2015

Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

Result type

Technology appraisal guidance

Published

2 October 2019

carried out to compare the clinical effectiveness of bendamustine with chlorambucil at the higher dose used in the Chronic Lymphocytic...